Acceder
  1. Inicio
  2. Perfil de Markusrunner
  3. Participaciones

Participaciones del usuario Markusrunner

Markusrunner 13/03/12 21:24
Ha respondido al tema Threshold Pharmaceuticals, Inc (THLD): Opiniones
Enola como esperas que se comporte mañana THLD? Me refiero si abrira con un buen gap al alza o sera algo similar a estos dias hasta que sepamos algo mas concreto de los avances en sus ensayos (hasta donde ellos quieran contar claro esta)? Segun lo dicho son los grandes protagonistas mañana si no me equivoco!! Saludos
Ir a respuesta
Markusrunner 13/03/12 17:25
Ha respondido al tema Zalicus
Yo compre ayer 1000€ a 1,03$ a ver si hay suerte y nos dan noticias agradable con vistas a largo plazo. Saludos
Ir a respuesta
Markusrunner 12/03/12 17:47
Ha respondido al tema Zalicus
Buenas Enola y demas foreros adjunto info. sobre ZLCS: Zalicus (ZLCS) Buy Limit: $2. Target Price: $7 in 2012. ZLCS has one technology for pain pathways, and another that develops combinations of approved drugs to combat diseases. How do they do it? The company’s high-tech assay equipment identifies synergistic combinations between already-existing drugs in an effort to better target diseases. In spite of the failure of their first two drugs, they merged with privately-held Neuromed in a deal that is very beneficial for both sides. Exalgo for pain was approved in 2010, and that roll out plus additional partnership announcements in 2011 will drive the stock higher.
Ir a respuesta
Markusrunner 12/03/12 17:32
Ha respondido al tema Threshold Pharmaceuticals, Inc (THLD): Opiniones
Este hilo engancha mucho... no es bueno para ludopatas jejej Yo tengo otro tiro disponible para nuestras THLD pero no estoy seguro de que hacer... Veo que vosotros vais muy fuertes, teneis mucha munición!!!
Ir a respuesta
Markusrunner 12/03/12 17:27
Ha respondido al tema Threshold Pharmaceuticals, Inc (THLD): Opiniones
Lo siento jejeje es que uno se excita en exceso con el nasdaq!!! Esto he encontrado sobre ZLCS: Zalicus (ZLCS) Buy Limit: $2. Target Price: $7 in 2012. ZLCS has one technology for pain pathways, and another that develops combinations of approved drugs to combat diseases. How do they do it? The company’s high-tech assay equipment identifies synergistic combinations between already-existing drugs in an effort to better target diseases. In spite of the failure of their first two drugs, they merged with privately-held Neuromed in a deal that is very beneficial for both sides. Exalgo for pain was approved in 2010, and that roll out plus additional partnership announcements in 2011 will drive the stock higher.
Ir a respuesta